References
1. Rehman A. Acute immune thrombocytopenic purpura in children. Turk J
Hematol. 2007;24:41-51.
2. Bussel JB MC. Lanzkowsky’s Manual of Pediatric Hematology and
Oncology 6th ed. ed: Elsevier; 2016.
3. Sandoval C, Visintainer P, Ozkaynak MF, Tugal O, Jayabose S. Clinical
features and treatment outcomes of 79 infants with immune
thrombocytopenic purpura. Pediatric blood & cancer. 2004;42(1):109-12.
4. Masamune Higashigawa TM, Ayako Yoshino, Kazuyuki Matsuda, Mitsue Ito,
Tomoaki Maji and Ryouji Ichimi. Incidence of childhood primary immune
thrombocytopenic purpura. Pediatrics International 2015;57:1041–3. doi:
doi: 10.1111/ped.12788.
5. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM,
Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi
MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kühne T, Ruggeri M,
George JN. Standardization of terminology, definitions and outcome
criteria in immune thrombocytopenic purpura of adults and children:
report from an international working group. Blood. 2009;113(11):2386-93.
Epub 2008/11/14. doi: 10.1182/blood-2008-07-162503. PubMed PMID:
19005182.
6. Chan H, Moore JC, Finch CN, Warkentin TE, Kelton JG. The IgG
subclasses of platelet‐associated autoantibodies directed against
platelet glycoproteins IIb/IIIa in patients with idiopathic
thrombocytopenic purpura. British journal of haematology.
2003;122(5):818-24.
7. Bolton-Maggs P. Idiopathic thrombocytopenic purpura. Archives of
disease in childhood. 2000;83(3):220-2.
8. Beck CE, Nathan PC, Parkin PC, Blanchette VS, Macarthur C.
Corticosteroids versus intravenous immune globulin for the treatment of
acute immune thrombocytopenic purpura in children: a systematic review
and meta-analysis of randomized controlled trials. J Pediatr.
2005;147(4):521-7. Epub 2005/10/18. doi: 10.1016/j.jpeds.2005.04.032.
PubMed PMID: 16227040.
9. Bansal D, Bhamare TA, Trehan A, Ahluwalia J, Varma N, Marwaha RK.
Outcome of chronic idiopathic thrombocytopenic purpura in children.
Pediatr Blood Cancer. 2010;54(3):403-7. Epub 2009/11/13. doi:
10.1002/pbc.22346. PubMed PMID: 19908301.
10. D’Orazio JA, Neely J, Farhoudi N. ITP in children: pathophysiology
and current treatment approaches. Journal of pediatric
hematology/oncology. 2013;35(1):1-13.
11. Kühne T. Advances in chemical pharmacotherapy for the treatment of
pediatric immune thrombocytopenia. Expert Opinion on Pharmacotherapy.
2018;19(7):667-76. doi: 10.1080/14656566.2018.1458091.
12. Kühne T. Treatment of pediatric primary immune thrombocytopenia with
thrombopoietin receptor agonists. Semin Hematol. 2015;52(1):25-30. Epub
2015/01/13. doi: 10.1053/j.seminhematol.2014.10.004. PubMed PMID:
25578416.
13. Ehrlich LA, Kwitkowski VE, Reaman G, Ko CW, Nie L, Pazdur R, Farrell
AT. US Food and Drug Administration approval summary: Eltrombopag for
the treatment of pediatric patients with chronic immune (idiopathic)
thrombocytopenia. Pediatric blood & cancer. 2017;64(12):e26657.
14. Neunert C, Despotovic J, Haley K, Lambert MP, Nottage K, Shimano K,
Bennett C, Klaassen R, Stine K, Thompson A. Thrombopoietin receptor
agonist use in children: data from the pediatric ITP consortium of North
America ICON2 Study. Pediatric blood & cancer. 2016;63(8):1407-13.
15. Lee MS, Kim WC. Intracranial hemorrhage associated with idiopathic
thrombocytopenic purpura: report of seven patients and a meta-analysis.
Neurology. 1998;50(4):1160-3. Epub 1998/05/05. doi:
10.1212/wnl.50.4.1160. PubMed PMID: 9566417.
16. Heitink-Pollé KM, Nijsten J, Boonacker CW, de Haas M, Bruin MC.
Clinical and laboratory predictors of chronic immune thrombocytopenia in
children: a systematic review and meta-analysis. Blood.
2014;124(22):3295-307. Epub 2014/10/12. doi:
10.1182/blood-2014-04-570127. PubMed PMID: 25305206.
17. Kühne T, Imbach P, Bolton-Maggs PH, Berchtold W, Blanchette V,
Buchanan GR, Group ICIS. Newly diagnosed idiopathic thrombocytopenic
purpura in childhood: an observational study. The lancet.
2001;358(9299):2122-5.
18. Deel MD, Kong M, Cross KP, Bertolone SJ. Absolute lymphocyte counts
as prognostic indicators for immune thrombocytopenia outcomes in
children. Pediatr Blood Cancer. 2013;60(12):1967-74. Epub 2013/09/17.
doi: 10.1002/pbc.24628. PubMed PMID: 24038723.
19. Farhangi H, Ghasemi A, Banihashem A, Badiei Z, Jarahi L, Eslami G,
Langaee T. Clinical Features and Treatment Outcomes of Primary Immune
Thrombocytopenic Purpura in Hospitalized Children Under 2-Years Old.
Iranian journal of pediatric hematology and oncology. 2016;6(1):24.
20. Akbayram S, Dogan M, Ustyol L, Akgun C, Peker E, Bilici S, Caksen H,
Oner AF. The clinical outcome of 260 pediatric ITP patients in one
center. Clin Appl Thromb Hemost. 2011;17(6):E30-5. Epub 2010/08/18. doi:
10.1177/1076029610379849. PubMed PMID: 20713486.
21. Tamminga R, Berchtold W, Bruin M, Buchanan GR, Kühne T. Possible
lower rate of chronic ITP after IVIG for acute childhood ITP an analysis
from registry I of the Intercontinental Cooperative ITP Study Group
(ICIS). Br J Haematol. 2009;146(2):180-4. Epub 2009/05/27. doi:
10.1111/j.1365-2141.2009.07743.x. PubMed PMID: 19466971.
22. Yacobovich J, Revel-Vilk S, Tamary H. Childhood immune
thrombocytopenia–who will spontaneously recover? Semin Hematol.
2013;50 Suppl 1:S71-4. Epub 2013/05/17. doi:
10.1053/j.seminhematol.2013.03.013. PubMed PMID: 23664522.
23. Baronci C, Pansini V, Funaro D, Coletti V, Caruso R, Rossi GD.
Idiopathic thrombocytopenic purpura (ITP) in children. Pediatric blood
& cancer. 2006;47(S5):665-7.
24. Psaila B, Petrovic A, Page LK, Menell J, Schonholz M, Bussel JB.
Intracranial hemorrhage (ICH) in children with immune thrombocytopenia
(ITP): study of 40 cases. Blood. 2009;114(23):4777-83. Epub 2009/09/22.
doi: 10.1182/blood-2009-04-215525. PubMed PMID: 19767509; PMCID:
PMC2786288.
25. Sabhan AH, Al-Jadiry MF, Ghali HH, Abed WM, Al-Hadad SA. Chronic
immune thrombocytopenic purpura in children overview of 60 patients.
Pediatric Hematology Oncology Journal. 2016;1(1):9-12.
26. Oved JH, Lee CS, Bussel JB. Treatment of children with persistent
and chronic idiopathic thrombocytopenic purpura: 4 infusions of
rituximab and three 4-day cycles of dexamethasone. The Journal of
pediatrics. 2017;191:225-31.
27. Liang Y, Zhang L, Gao J, Hu D, Ai Y. Rituximab for children with
immune thrombocytopenia: a systematic review. PLoS One.
2012;7(5):e36698. Epub 2012/06/06. doi: 10.1371/journal.pone.0036698.
PubMed PMID: 22666325; PMCID: PMC3364261.
28. Sato T, Morita I, Fujita H, Ono M, Kimishima A, Tomiyama J, Murota
S. Pharmacological characterization of cepharanthin in chronic
idiopathic thrombocytopenic purpura. Platelets. 2001;12(3):156-62. Epub
2001/04/17. doi: 10.1080/09537100120039334. PubMed PMID: 11304417.
29. Yamazaki T, Shibuya A, Ishii S, Miura N, Ohtake A, Sasaki N, Araki
R, Ota Y, Fujiwara M, Miyajima Y. High‐dose Cepharanthin for pediatric
chronic immune thrombocytopenia in Japan. Pediatrics International.
2017;59(3):303-8.
30. Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj
A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M.
Romiplostim in children with immune thrombocytopenia: a phase 3,
randomised, double-blind, placebo-controlled study. Lancet.
2016;388(10039):45-54. Epub 2016/04/23. doi:
10.1016/s0140-6736(16)00279-8. PubMed PMID: 27103127.
31. Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J,
Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB. Eltrombopag
for the treatment of children with persistent and chronic immune
thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled
study. The Lancet Haematology. 2015;2(8):e315-e25.
32. Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E,
Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N,
Holzhauer S. Eltrombopag for children with chronic immune
thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled
trial. The Lancet. 2015;386(10004):1649-58.